<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="334982">
  <stage>Registered</stage>
  <submitdate>5/01/2010</submitdate>
  <approvaldate>4/01/2011</approvaldate>
  <actrnumber>ACTRN12611000001998</actrnumber>
  <trial_identification>
    <studytitle>Regional delivery of prophylactic antibiotics in total knee arthroplasty via an intraosseous route
	A tissue penetration study</studytitle>
    <scientifictitle>Total Knee Arthroplasty patients given intraosseous or systemic prophylactic antibiotics and tissue concentrations measured</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Infected total knee arthroplasty</healthcondition>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Surgical techniques</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Immediately following tourniquet inflation Group 1 would then receive a single 1g dose of cefazolin via an intraosseous cannula into the proximal tibia. The cefazolin would be administered in 200ml of saline solution.</interventions>
    <comparator>Group 2 will receive a single 1g dose of cefazolin via the systemic route, ten minutes prior to tourniquet inflation.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary outcome is Cephazolin concentration in tissue. Seven samples will be taken from each patient, 4 fat samples and 3 bone samples.  Each sample will be approximately the size of a pinhead.  Bone samples will be taken from the femur only to ensure no direct contamination from the site of injection (tibia).  Due to the small size of the samples it is anticipated that there will be no detrimental effect on the patient whatsoever.  Samples will be stored at Middlemore hospital lab at -90 degrees Celsius, before being sent to Christchurch for analysis using a technique called high performance liquid chromatography (HPLC), which will determine the concentration of Cefazolin in each sample.</outcome>
      <timepoint>15 minute intervals post administration</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Total Knee Replacement patients
Osteoarthritis
Body Mass Index (BMI)&lt;30</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Active infection
Impaired renal function
Allergiy to antibiotic</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed envelopes opened at time of enrollment</concealment>
    <sequence>computer generated random sequence</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Bio-availability</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/04/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>22</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Middlmore Hospital</primarysponsorname>
    <primarysponsoraddress>Middlemore Hospital
PO Box 93311	
Otahuhu	
Auckland</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>CCRep</fundingname>
      <fundingaddress>CCRep Innovation Fund 
Level 3, Support Building, 
Middlemore Hospital, Otahuhu, Auckland</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this study is to assess the feasibility of the intraosseous route in providing higher local tissue concentrations of prophylactic antibiotics in knee replacement surgery.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern X Ethics Commitee</ethicname>
      <ethicaddress>Ministry of Health
650 Great South Road
Private Bag 92522 
Wellesley Street
Auckland</ethicaddress>
      <ethicapprovaldate>1/03/2009</ethicapprovaldate>
      <hrec>NTX/10/02/002</hrec>
      <ethicsubmitdate>5/01/2009</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Simon Young</name>
      <address>Middlemore Hospital
PO Box 93311	
Otahuhu	
Auckland</address>
      <phone>+6421616183</phone>
      <fax />
      <email>simonwyoung@gmail.com</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Simon Young</name>
      <address>Middlemore Hospital
PO Box 93311	
Otahuhu	
Auckland</address>
      <phone>+6421616183</phone>
      <fax />
      <email>simonwyoung@gmail.com</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>